Moffitt Cancer Center and Cryoport Announce Strategic Collaboration
Moffitt Cancer Center and Cryoport (NASDAQ: CYRX) announced a strategic collaboration where Cryoport's CRYOGENE will provide state-of-the-art biorepository services at Moffitt's Speros FL campus in Pasco County, Florida. The collaboration aims to support the development of cell and gene therapies, with the industry projected to reach over $97 billion by 2033 at an 18.3% CAGR from 2024-2033.
The facility will be located adjacent to Moffitt's 250,000-square-foot Discovery & Innovation Center and will enhance collaboration across Moffitt's expanding health system. CRYOGENE, which currently manages over 25 million samples across its Texas locations, will provide biostorage technologies and logistics services to support patient treatments and medical research.
This partnership is part of Speros' master development plan, which includes multiple phases focusing on cell and gene therapies, AI, biotech, and other life sciences initiatives. Construction of Moffitt's outpatient and proton therapy center began in 2023, with completion scheduled for 2026.
Il Moffitt Cancer Center e Cryoport (NASDAQ: CYRX) hanno annunciato una collaborazione strategica in cui CRYOGENE di Cryoport fornirà servizi di biorepository all'avanguardia presso il campus Speros FL di Moffitt a Pasco County, Florida. La collaborazione mira a supportare lo sviluppo di terapie cellulari e geniche, con l'industria che si prevede raggiunga oltre 97 miliardi di dollari entro il 2033, con un CAGR del 18,3% dal 2024 al 2033.
La struttura sarà situata adiacente al centro Discovery & Innovation di Moffitt, che occupa 250.000 piedi quadrati e migliorerà la collaborazione tra il crescente sistema sanitario di Moffitt. CRYOGENE, che attualmente gestisce oltre 25 milioni di campioni nelle sue sedi in Texas, fornirà tecnologie di bioconservazione e servizi logistici per supportare i trattamenti per i pazienti e la ricerca medica.
Questa partnership fa parte del piano di sviluppo master di Speros, che include più fasi focalizzate su terapie cellulari e geniche, intelligenza artificiale, biotecnologia e altre iniziative nelle scienze della vita. La costruzione del centro ambulatoriale e del centro di terapia protonica di Moffitt è iniziata nel 2023, con completamento previsto per il 2026.
El Moffitt Cancer Center y Cryoport (NASDAQ: CYRX) anunciaron una colaboración estratégica en la que CRYOGENE de Cryoport proporcionará servicios de biobanco de última generación en el campus Speros FL de Moffitt en el condado de Pasco, Florida. La colaboración tiene como objetivo apoyar el desarrollo de terapias celulares y génicas, con la industria proyectada para alcanzar más de 97 mil millones de dólares para 2033, con un CAGR del 18,3% de 2024 a 2033.
La instalación estará ubicada adyacente al centro Discovery & Innovation de Moffitt, que abarca 250,000 pies cuadrados, y mejorará la colaboración en todo el sistema de salud en expansión de Moffitt. CRYOGENE, que actualmente gestiona más de 25 millones de muestras en sus ubicaciones de Texas, proporcionará tecnologías de bioconservación y servicios logísticos para apoyar los tratamientos de los pacientes y la investigación médica.
Esta asociación es parte del plan maestro de desarrollo de Speros, que incluye múltiples fases enfocadas en terapias celulares y génicas, inteligencia artificial, biotecnología y otras iniciativas en ciencias de la vida. La construcción del centro ambulatorio y del centro de terapia protónica de Moffitt comenzó en 2023, con una finalización programada para 2026.
모피트 암 센터와 크라이오포트(NASDAQ: CYRX)는 크라이오포트의 CRYOGENE이 플로리다주 파스코 카운티의 모피트 스페로스 FL 캠퍼스에서 최첨단 생물 보관 서비스를 제공하는 전략적 협력관계를 맺었다고 발표했다. 이 협력은 2024년부터 2033년까지 연평균 18.3% 성장률로 2033년까지 970억 달러를 초과할 것으로 예상되는 세포 및 유전자 치료의 개발을 지원하는 것을 목표로 한다.
이 시설은 모피트의 25만 평방피트 규모의 Discovery & Innovation Center에 인접해 위치하며, 모피트의 확장되는 건강 시스템 간의 협력을 강화할 것이다. 현재 텍사스 지역에서 2,500만 개 이상의 샘플을 관리하는 CRYOGENE은 환자 치료와 의학 연구를 지원하기 위해 생물 저장 기술 및 물류 서비스를 제공할 것이다.
이 파트너십은 세포와 유전자 치료, 인공지능, 생명공학 및 기타 생명 과학 이니셔티브에 중점을 둔 여러 단계로 구성된 스페로스의 마스터 개발 계획의 일부이다. 모피트의 외래환자 및 양성자 치료 센터의 건설은 2023년에 시작되었고, 2026년에 완공될 예정이다.
Le Moffitt Cancer Center et Cryoport (NASDAQ : CYRX) ont annoncé une collaboration stratégique dans laquelle CRYOGENE de Cryoport fournira des services de biobanque à la pointe de la technologie sur le campus Speros FL de Moffitt dans le comté de Pasco, en Floride. La collaboration vise à soutenir le développement des thérapies cellulaires et géniques, avec une prévision selon laquelle l'industrie atteindra plus de 97 milliards de dollars d'ici 2033, avec un TCAC de 18,3 % de 2024 à 2033.
La structure sera située à côté du centre Discovery & Innovation de 250,000 pieds carrés de Moffitt et améliorera la collaboration au sein du système de santé en expansion de Moffitt. CRYOGENE, qui gère actuellement plus de 25 millions d'échantillons dans ses installations au Texas, fournira des technologies de bioconservation et des services logistiques pour soutenir les traitements des patients et la recherche médicale.
Ce partenariat fait partie du plan de développement master de Speros, qui comprend plusieurs phases axées sur les thérapies cellulaires et géniques, l'IA, la biotechnologie et d'autres initiatives dans les sciences de la vie. La construction du centre de soins ambulatoires et du centre de thérapie protonique de Moffitt a commencé en 2023, avec une date d'achèvement prévue en 2026.
Das Moffitt Cancer Center und Cryoport (NASDAQ: CYRX) haben eine strategische Zusammenarbeit bekannt gegeben, bei der CRYOGENE von Cryoport modernste Biobank-Dienstleistungen auf dem Speros FL-Campus von Moffitt im Pasco County, Florida, bereitstellen wird. Die Zusammenarbeit zielt darauf ab, die Entwicklung von Zell- und Gentherapien zu unterstützen, wobei die Branche voraussichtlich bis 2033 über 97 Milliarden US-Dollar erreichen wird, mit einer CAGR von 18,3 % von 2024 bis 2033.
Die Einrichtung wird direkt neben dem 250.000 Quadratfuß großen Discovery & Innovation Center von Moffitt liegen und die Zusammenarbeit innerhalb des wachsenden Gesundheitssystems von Moffitt verbessern. CRYOGENE, das derzeit über 25 Millionen Proben an seinen Standorten in Texas verwaltet, wird Biostorage-Technologien und Logistikdienstleistungen bereitstellen, um Patiententherapien und medizinische Forschung zu unterstützen.
Diese Partnerschaft ist Teil des Master-Entwicklungsplans von Speros, der mehrere Phasen umfasst, die sich auf Zell- und Gentherapien, KI, Biotechnologie und andere Initiativen in den Lebenswissenschaften konzentrieren. Der Bau von Moffitts ambulantem und Protonenbehandlungszentrum begann 2023, und die Fertigstellung ist für 2026 geplant.
- Strategic partnership with major cancer center expands CYRX's market presence
- Access to growing cell and gene therapy market projected at $97B by 2033
- Integration with Moffitt's 775-acre life sciences campus provides growth opportunities
- Expansion of biorepository services into new Florida location
- None.
Insights
This strategic collaboration marks a pivotal advancement in the cell and gene therapy infrastructure landscape. The partnership leverages CRYOGENE's biorepository expertise within Moffitt's ambitious 775-acre Speros campus, positioning it as a potential cornerstone in the
The facility's integration into Moffitt's 250,000-square-foot Discovery & Innovation Center creates a powerful synergy for accelerating therapeutic development. With CRYOGENE's track record of managing over 25 million samples and the projected
Think of this as building a highly sophisticated biological vault right next to a major research hub - it's like having a specialized bank that stores and manages critical biological assets directly connected to where groundbreaking research happens. This proximity and integration will likely reduce development timelines and costs while improving treatment accessibility.
The strategic placement of CRYOGENE's facility within the Speros campus represents a significant infrastructure development that will likely catalyze the region's transformation into a major biotech hub. The facility's location adjacent to Moffitt's research center creates an integrated ecosystem that will streamline the complex logistics of cell and gene therapy development.
This integration addresses a critical bottleneck in advanced therapy development - the need for seamless coordination between research, storage and clinical application. By centralizing these functions, the collaboration could significantly reduce the time-to-treatment window, a important factor in patient outcomes. It's similar to how Amazon's strategic warehouse placements revolutionized retail delivery - this setup could do the same for personalized medicine delivery.
Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services
"Our goal is to make Speros the cell and gene therapy capital of the world," said Patrick Hwu, M.D., president and CEO of Moffitt. "With the addition of CRYOGENE, we will accelerate discovery by igniting collaborations and partnerships across disciplines to bring new therapies to patients faster and save more lives. This collaboration builds upon Moffitt's longstanding partnership with Cryoport's CRYOGENE and serves as an initial step in transforming our campus into a global epicenter of innovation."
"Having CRYOGENE's facility with a seasoned team located directly on the Speros campus and at Moffitt's research facility provides top-level research and biotech companies with the critical tools and infrastructure to immediately operate more effectively," said Marshall Griswold, CEO of CRYOGENE. "We all share a common goal to save and improve patients' lives, and our team is ready and eager to assist Speros and Moffitt in fulfilling this mission."
The addition of CRYOGENE's biostorage facility will lay the foundation for Moffitt's Speros campus as a global epicenter for patient treatment and research in cell and gene therapies, immunotherapies, radiopharmaceuticals, proton therapies and other expanding technologies and treatment pathways. This facility will be included in the initial phase of the development of Speros and is located adjacent to Moffitt's 250,000-square-foot Discovery & Innovation Center for research.
Jerrell Shelton, CEO of Cryoport, added, "We are honored to be partnering with Moffitt's Speros campus to support the needs of research and cancer patients receiving medical care at this world class life sciences campus and cancer center. Through our collaboration, Cryoport's CRYOGENE will provide cutting-edge biostorage technologies and logistics services to support patients' treatments as well as the invaluable medical and biopharmaceutical research taking place at Moffitt to accelerate scientific discovery and save lives today and tomorrow."
Biorepositories play a crucial role in the development and storage of cell and gene therapies, an industry projected to reach over
The facility will enhance collaboration across Moffitt's expanding health system while also supporting emerging blood sciences and organ and tissue biobanking protocols. The biorepository will provide streamlined access to critical research and clinical activities, along with essential capabilities for distributing research and treatment materials.
"Bringing a biorepository industry leader like Cryoport to our emerging life sciences campus is a foundational component of Speros in providing science as a service," said Sabi Singh, Moffitt's Chief Operating Officer. "Speros will be a place where paradigm-shifting science impacts human health. This collaboration with Cryoport will drive other academic, clinical, life sciences, pharmaceutical and research institutions to join our mission."
Speros' master development plan for its global innovation life sciences campus spans multiple phases. Speros will expand the cancer center's global footprint and will serve as a dynamic nexus for the convergence of biotech and life sciences. In its initial phases of development, Speros will focus on mission-critical activities, including cell and gene therapies, artificial intelligence, biotech, business incubators and accelerators, drug discovery, bioengineering, metabolism, data science, machine learning, health care, life sciences, basic research and complementary amenities. Construction on Moffitt's outpatient and proton therapy center began in early 2023 and is scheduled for completion by 2026.
CRYOGENE focuses on the secure storage of biological material and provides innovative biostorage solutions to the research, biotech and pharmaceutical industries. With over 25 million samples securely stored and managed under its care, CRYOGENE provides the highest quality secure sample storage services available. CRYOGENE has two locations in
About Speros FL
Speros FL's mission is to unleash collective genius to improve human life. As a global innovation hub for science, technology and health care, Speros brings people and resources together to solve complex problems to advance hope and a healthier future. A mission-driven real estate venture, Speros realizes this vision by developing a comprehensive ecosystem of converging industries, including artificial intelligence, biotech, business incubators and accelerators, cell and gene therapies, data, health care, life sciences, machine learning, research and academia, and complementary amenities. For more information, visit SperosFL.org.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for cell & gene therapies that enable manufacturers, contract development manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers to carry out their respective business with certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions, which include advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
Its corporate headquarters, located in
For more information, http://www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the strategic collaboration with Moffitt Cancer Center, including the potential impact on future revenue and revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/moffitt-cancer-center-and-cryoport-announce-strategic-collaboration-302350250.html
SOURCE Cryoport, Inc.
FAQ
What is the value of the cell and gene therapy market that CYRX is targeting through the Moffitt partnership?
How many biological samples does CYRX's CRYOGENE currently manage?
When will the Moffitt Cancer Center facility partnering with CYRX be completed?
What services will CYRX's CRYOGENE provide at the Speros campus?
Where will CYRX's new biorepository facility be located at Speros?
